News | Cath Lab | June 22, 2017

Vascular Solutions Recalls Venture Catheters That May Split or Separate During Use

FDA identified this as a Class 1 recall due to the possibility of components embolizing

The Vascular Solutions Venture catheters were recalled due to tip separation

June 22, 2017 — The U.S. Food and Drug Administration (FDA) has identified Vascular Solutions’ recent recall of its Venture catheters as a Class I recall, it announced this week. This is the most serious type of recall, because the FDA said use of these devices may cause serious injuries or death.

Vascular Solutions initiated a voluntary recall of the guidewires April 25, 2017. The company said there is a risk of the catheter tip splitting or separating during use. Excess material at the tip of the catheter may separate and could embolize into the patient's bloodstream. This can result in serious adverse health consequences such as the development of blood clots, embolism of the excess material to vital organs, or death.

Recall is for Venture RX Catheter (Model 5820), Venture OTW (Model 5821) and Venture CS  Catheter (Model 5822). These devices were distribution between May 7, 2015 to April 19, 2017, and manufactured between May 7, 2015 to March 31, 2017. The recall includes 7,054 nationwide in the U.S.

The Venture catheter is intended for directing, steering, controlling and supporting a guidewire to access veins and arteries in the arms, legs, hands, feet, and heart muscle (myocardium). Certain models may also administer saline fluids or drugs into blood vessels.

The company sent an urgent medical device recall letter to all affected customers. The letter asked distributors and customers to identify and remove any affected Venture catheters from inventory and quarantine. This includes completing a field safety notice and a customer inventory form. After all the affected catheters are returned, customers are asked to complete the Vascular Solutions Inc. Distributor Inventory Form, and return it via email to [email protected] Upon receipt of the form, Vascular Solutions' customer service department will provide a return authorization number and arrange for return of affected Venture catheters. A credit will be offered after affected devices have been returned, the company said.

Healthcare professionals and consumers may contact Vascular Solutions at (888) 240-6001 Monday through Friday, between the hours of 8 a.m. and 5 p.m. Central Time, or by e-mail at [email protected] with any questions related to this recall.

For a complete list of recalled product codes and lot numbers go to

Related Content:

VIDEO: Basics of Interventional Guidewire Design and Function

Understanding the Design and Function of Guidewire Technology

The Basics of Guide Wire Technology


Related Content

Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab | November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab | November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Overlay Init